These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 34262010)
1. Isolated Adrenocorticotropic Hormone Deficiency Associated with Severe Hyperkalemia During Pembrolizumab Therapy in a Patient with Ureteral Cancer and an Ileal Conduit: A Case Report and Literature Review. Hinata Y; Ohara N; Sakurai Y; Koda R; Yoneoka Y; Takada T; Hara N; Nishiyama T Am J Case Rep; 2021 Jul; 22():e931639. PubMed ID: 34262010 [TBL] [Abstract][Full Text] [Related]
2. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review. Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581 [TBL] [Abstract][Full Text] [Related]
3. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases]. Gu YC; Liu Y; Xie C; Cao BS Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206 [TBL] [Abstract][Full Text] [Related]
4. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature. Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965 [TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report. Porntharukchareon T; Tontivuthikul B; Sintawichai N; Srichomkwun P J Med Case Rep; 2020 Sep; 14(1):171. PubMed ID: 32988414 [TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study. Cui K; Wang Z; Zhang Q; Zhang X Ann Transl Med; 2022 Mar; 10(5):251. PubMed ID: 35402601 [TBL] [Abstract][Full Text] [Related]
7. Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review. Iglesias P; Sánchez JC; Díez JJ Pituitary; 2021 Aug; 24(4):630-643. PubMed ID: 33761049 [TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor-induced isolated adrenocorticotropic hormone deficiency: a systematic review. Wang F; Shi X; Yu X; Yang Y Front Endocrinol (Lausanne); 2024; 15():1326684. PubMed ID: 38318292 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy-induced isolated ACTH deficiency in cancer therapy. Iglesias P; Peiró I; Biagetti B; Paja-Fano M; Cobo DA; García Gómez C; Mateu-Salat M; Genua I; Majem M; Riudavets M; Gavira J; Lamas C; Fernández Pombo A; Guerrero-Pérez F; Villabona C; Cabezas Agrícola JM; Webb SM; Díez JJ Endocr Relat Cancer; 2021 Oct; 28(12):783-792. PubMed ID: 34609950 [TBL] [Abstract][Full Text] [Related]
10. Isolated Adrenocorticotropic Hormone Deficiency Presenting with Severe Hyponatremia and Rhabdomyolysis: A Case Report and Literature Review. Komatsu T; Ohara N; Hirota N; Yoneoka Y; Tani T; Terajima K; Ozawa T; Sone H Am J Case Rep; 2019 Dec; 20():1857-1863. PubMed ID: 31827062 [TBL] [Abstract][Full Text] [Related]
11. Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review. Oğuz SH; Ünlütürk U; Aksoy S; Erbas T Immunotherapy; 2021 Oct; 13(14):1157-1163. PubMed ID: 34387129 [TBL] [Abstract][Full Text] [Related]
12. Pituitary-related immune adverse events induced by programmed death Protein-1 inhibitors differ clinically from hypophysitis. Yang L; Zhang Y; Chen X; Liu K; Zhou Y; Wang S Clin Endocrinol (Oxf); 2024 Aug; 101(2):130-139. PubMed ID: 38753540 [TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer. Kurokawa K; Mitsuishi Y; Shimada N; Ito N; Ogiwara M; Miura K; Asao T; Ko R; Shukuya T; Shibayama R; Goto H; Takahashi K Thorac Cancer; 2023 Feb; 14(5):442-449. PubMed ID: 36523162 [TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency. Manaka K; Sato J; Takeuchi M; Watanabe K; Kage H; Kawai T; Sato Y; Miyagawa T; Yamada D; Kume H; Sato S; Nagase T; Iiri T; Nangaku M; Makita N Sci Rep; 2021 Jun; 11(1):11617. PubMed ID: 34078988 [TBL] [Abstract][Full Text] [Related]
15. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. Reynolds KL; Guidon AC Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825 [TBL] [Abstract][Full Text] [Related]
16. Life threatening hyperkalemia and acidosis secondary to trimethoprim-sulfamethoxazole treatment. Margassery S; Bastani B J Nephrol; 2001; 14(5):410-4. PubMed ID: 11730276 [TBL] [Abstract][Full Text] [Related]
17. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer. Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588 [TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab-Induced Hypophysitis With Isolated Adrenocorticotropic Hormone (ACTH) Deficiency: A Rare Immune-Mediated Adverse Event. Doodnauth AV; Klar M; Mulatu YS; Malik ZR; Patel KH; McFarlane SI Cureus; 2021 Jun; 13(6):e15465. PubMed ID: 34123679 [TBL] [Abstract][Full Text] [Related]
19. Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report. Tanaka S; Kushimoto M; Nishizawa T; Takubo M; Mitsuke K; Ikeda J; Fujishiro M; Ogawa K; Tsujino I; Suzuki Y; Abe M Clin Diabetes Endocrinol; 2020; 6():1. PubMed ID: 31921440 [TBL] [Abstract][Full Text] [Related]
20. Hypophysitis Induced by Sintilimab in the Treatment of Bladder Cancer: A Case Report. Li R; Jiang B; Zhu Y; Gao L; Zhou Y; Yang S Endocr Metab Immune Disord Drug Targets; 2024; 24(5):606-610. PubMed ID: 37818555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]